TSS
RUBY

Two Sigma Securities’s Rubius Therapeutics, Inc RUBY Stock Holding History

Two Sigma Securities’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-31,849
Closed -$14K – 3463
2022
Q3 		$14K Buy
+31,849
New +$23.9K ﹤0.01% 2352
2021
Q1 		– Sell
-23,606
Closed -$179K – 1923
2020
Q4 		$179K Buy
+23,606
New +$140K ﹤0.01% 1439

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Securities's RUBY Position: Q4 2022 in Review

Two Sigma Securities sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 31,849 shares — an estimated $14K sold.

Two Sigma Securities first reported a position in RUBY in Q4 2020 and held it in 2 quarters. The position peaked at $179K in Q4 2020. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Two Sigma Securities reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Two Sigma Securities sold 31,849 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $14K.
  • Two Sigma Securities first reported a position in Rubius Therapeutics, Inc in Q4 2020 and held it in 2 quarters.
  • Two Sigma Securities's Rubius Therapeutics, Inc position peaked at $179K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Two Sigma Securities's 13F filing for Q4 2022, filed 14 Feb 2023.